


WHAT IS CLAIMED IS:

1. A monocyclic peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (I):



wherein

X3 is absent or any amino acid;

X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);

X5 is Cit, Glu, Gly, substituted Gly, Leu, Ile, beta-Ala, Ala, Lys, Asn, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, or Asp;

X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val;

X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, alkoxy, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, substituted Phe, Tyr, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, Lys(b-Ala), Lys(Gly), Lys(Benzyl, Ac), Lys(butyl, Ac), Lys(isobutyl,Ac), Lys(propyl,Ac), or Trp;

X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);

X10 is Tyr, or substituted Tyr, unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, cyano, cycloalkyl, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 2Quin, 3Quin, 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), Acvc, alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, cyclohexylAla, Lys, or Aib;

X13 is any amino acid;

X14 is any amino acid;

and

i) X15 is any amino acid other than His, (D)His, substituted or unsubstituted His, 2Pal, 3Pal, or 4Pal; X16 is Sarc, aMeLeu, (D)NMeTyr, His, (D)Thr, bAla, Pro, or (D)Pro; and the peptide inhibitor is other than


Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[THP]-[Lys(Ac)]-NNPG-NH₂;
 Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-
 [Lys(Ac)]-NN-[Sarc]-NH₂;
 Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-
 [a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂; or
 Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
 [Lys(Ac)]-N-[Aib]-[bA]-NH₂;

or


ii) X15 is His, (D)His, substituted or unsubstituted His, 2Pal, 3Pal, 4Pal, 4TriazolAla, or 5Pyal; and X16 is absent, (D)aMeTyr, (D)NMeTyr or any amino acid other than THP, substituted or unsubstituted Phe, substituted or unsubstituted (D)Phe, substituted or unsubstituted His, substituted or unsubstituted (D)His, substituted or unsubstituted Trp, substituted or unsubstituted 2-Nal, or N-substituted Asp; and the compound is other than

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
 [Lys(Ac)]-N-H-NH₂;

wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



5Pyal is 5-pyrimidine substituted alanine:



and

wherein X4 and X9 form a disulfide bond or a thioether bond;

and

wherein the peptide inhibitor inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.

2. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein X15 is any amino acid other than His, (D)His, or substituted or unsubstituted His, 2Pal, 3Pal, or 4Pal; X16 is Sarc, aMeLeu, (D)NMeTyr, His, (D)Thr, bAla, Pro, or (D)Pro; and the compound is other than

Ac-[Abu]-QTWQC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-NNPG-NH₂;
 Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-
 [Lys(Ac)]-NN-[Sarc]-NH₂;
 Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-
 [a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂; or
 Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
 [Lys(Ac)]-N-[Aib]-[bA]-NH₂.

3. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Ia):

X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-Sarc (Ia)

wherein X4 and X9 form a disulfide bond or a thioether bond; X15 is any amino acid; and ; and the compound is other than

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-
 [Lys(Ac)]-NN-[Sarc]-NH₂; or
 Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-
 [a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

4. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Ib):

X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-(D)NMeTyr (Ib)


wherein X4 and X9 form a disulfide bond or a thioether bond; X15 is any amino acid.

5. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Ic):

X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-[Pal]-X16 (Ic)


wherein Pal is 2Pal, 3Pal, or 4Pal; X16 is absent;

wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine




and X4 and X9 form a disulfide bond or a thioether bond.

6. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Id):



wherein His' is His or 3-MeHis; X16 is absent; and X4 and X9 form a disulfide bond or a thioether bond.


7. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein X15 is any amino acid; X16 is bA, aMe(D)Tyr, (D)NMeTyr, Sarc, Pro, or (D)Pro; and the peptide inhibitor is other than



8. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein


X15 is any amino acid; X16 is bA, aMe(D)Tyr, (D)NMeTyr, Sarc, Pro, or (D)Pro,

and the compound is other than



9. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X15 is any amino acid; X16 is (D)NMeTyr, or Sarc; and the peptide inhibitor is other than



Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

10. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X15 is 3Quin, Asn, His, (D)His, (D)Leu, (D)Lys, 3-Pal, 4-Pal, Phe, substituted Phe, (D)Thr, substituted Trp or (D)Val; X16 is (D)NMeTyr, or Sarc; and the peptide inhibitor is other than

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-[Lys(Ac)]-NN-[Sarc]-NH₂; or

Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

11. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X16 is (D)NMeTyr.

12. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X16 is Sarc; and the peptide inhibitor is other than

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-[Lys(Ac)]-NN-[Sarc]-NH₂; or

Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

13. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X15 is His, (D)Lys, 3-Pal, or 4-Pal; X16 is (D)NMeTyr, or Sarc; and the peptide inhibitor is other than

Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

14. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X15 is Asn, His, (D), His, (D)Leu, (D)Lys, 3-Pal, substituted or unsubstituted Phe, (D)Thr, or (D)Val; X16 is (D)NMeTyr.

15. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X15 is 3Quin, Asn, His, (D)His, (D)Leu, (D)Lys, 3-Pal, 4-Pal, or substituted Trp;

X16 is Sarc; and the peptide inhibitor is other than

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-

[Lys(Ac)]-NN-[Sarc]-NH₂; or

Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-

[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

16. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein X15 is (3-Me)His, 3-Pal, or 4-Pal; and X16 is absent, Sarc or (D)NMeTyr.

17. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein X15 is (3-Me)His or 3-Pal; and X16 is absent or Sarc.

18. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein
X15 is 3-Pal; and X16 is Sarc.

19. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein
X15 is Asn, His, (D)Lys, or 3-Pal; X16 is (D)NMeTyr, or Sarc; and the peptide inhibitor is other than

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-

[Lys(Ac)]-NN-[Sarc]-NH₂;

Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-

[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂.

20. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein
X15 is 5-Pyal, (D)His, (1-Me)His, (3-Me)His, 2-Pal or 3-Pal; and X16 is absent; and the peptide inhibitor is other than

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-

[Lys(Ac)]-N-H-NH₂.

21. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein
X15 is 5-Pyal, (1-Me)His, or (3-Me)His; and X16 is absent.

22. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein

X15 is 5-Pyl or (3-Me)His; and X16 is absent.

23. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein X15 is His, (D)His, or substituted or unsubstituted His, 2Pal, 3Pal, 4Pal, or 5Pyl; and X16 is absent, (D)αMeTyr, (D)NMeTyr or any amino acid other than THP, substituted or unsubstituted Phe, substituted or unsubstituted (D)Phe, substituted or unsubstituted His, substituted or unsubstituted (D)His, substituted or unsubstituted Trp, substituted or unsubstituted 2-Nal, or N-substituted Asp.

24. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X4 or X9 is independently Cys, (D)Cys, α-MeCys, (D)Pen, or Pen; and the bond between X4 and X9 is a disulfide bond.

25. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X4 is (D)Pen, Pen, or Pen(sulfoxide).

26. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X4 is Pen.

27. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X9 is Cys, (D)Cys, or α-MeCys.

28. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-3, wherein X9 is Pen or (D)Pen.

29. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X9 is Pen.

30. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X4 is Pen and X9 is Pen, and the bond is a disulfide bond.

31. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X4 or X9 is Abu; and the bond between X4 and X9 is a thioether bond.

32. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-23, wherein X4 is Abu.

33. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-27 or 31-32, wherein X9 is Cys, (D)Cys, or α-MeCys.

34. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-26 or 28-32, wherein X9 is Pen or (D)Pen.

35. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-26 or 28-32, wherein X9 is Pen.

36. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-27 or 31-33, wherein X9 is Cys.

37. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-24, 27-29, or 31-32, wherein X4 is Abu and X9 is Cys or Pen, and the bond is a thioether bond.

38. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-24, 27-29, or 31-32, wherein X4 is Abu and X9 is Cys, and the bond is a thioether bond.

39. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IIa), (IIb), or (IIc):

Pen-X5-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-X16 (IIa),
Abu-X5-X6-X7-X8-Cys-X10-X11-X12-X13-X14-X15-X16 (IIb), or
Abu-X5-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-X16 (IIc),

wherein X5-X8 and X10-X14 are as described in claim 1; X15 is His, (D)His, or substituted or unsubstituted His, 2Pal, 3Pal, or 4Pal, and X16 is any amino acid; or X15 is any amino acid and X16 is Sarc; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.

40. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-39, wherein X15 is 2Pal, 3Pal, or 4Pal, and X16 is any amino acid.

41. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-39, wherein X15 is His or 3MeHis; and X16 is any amino acid.

42. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-39, wherein X15 is any amino acid and X16 is Sarc.

43. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-39, wherein X15 is any amino acid and X16 is (D)NMeTyr.

44. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-43, wherein X5 is Asn, Ser, Gln, or Glu.

45. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-43, wherein X5 is Asn, or Gln.

46. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-43, wherein X5 is Asn.

47. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IIIa), (IIIb), (IIIc), or (IIId):

Pen- Asn-X6-X7-X8-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (IIIa),


Pen-Gln-X6-X7-X8-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (IIIb),

Abu- Asn-X6-X7-X8-Cys-X10-X11-X12-X13-X14-[Pal]-X16 (IIIc), or

Abu-Gln-X6-X7-X8-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (IIId),

wherein X6-X8 and X10-X14 are as described in claim 1; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid;

wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

48. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IVa), (IVb), (IVc), or (IVd), (IVe), (IVf), (IVg), or (IVh):

Pen- Asn-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-Sarc (IVa),

Pen-Gln-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-Sarc (IVb),

Abu- Asn-X6-X7-X8-Cys-X10-X11-X12-X13-X14-X15-Sarc (IVc),

Abu-Gln-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-Sarc (IVd),

Pen- Asn-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (IVe),

Pen-Gln-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (IVf),

Abu- Asn-X6-X7-X8-Cys-X10-X11-X12-X13-X14-X15-(D)NMeTyr (IVg), or

Abu-Gln-X6-X7-X8-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (IVh),
wherein X6-X8 and X10-X14 are as described in claim 1; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

49. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-48, wherein X6 is Thr.

50. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Va), (Vb), (Vc), or (Vd):

Pen- Asn-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (Va),


Pen-Gln-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (Vb),

Abu- Asn-Thr-X7-X8-Cys-X10-X11-X12-X13-X14-[Pal]-X16 (Vc), or

Abu-Gln-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (Vd),

wherein X7-X8 and X10-X14 are as described in claim 1; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid;

wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

51. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIa), (VIb), (VIc), or (VIe), (VIf), (VIg), or (VIh):

Pen- Asn-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-X15-Sarc (VIa),

Pen-Gln-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-X15-Sarc (VIb),

Abu- Asn-Thr-X7-X8-Cys-X10-X11-X12-X13-X14-X15-Sarc (VIc),

Abu-Gln-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-X15-Sarc (VIe),

Pen- Asn-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIf),

Pen-Gln-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIg),

Abu- Asn-Thr-X7-X8-Cys-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIg) (SEQ ID NO:536),

or

Abu-Gln-Thr-X7-X8-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIh),

wherein X7-X8 and X10-X14 are as described in claim 1; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

52. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-51, wherein X8 is Gln, alpha-Me-Lys, alpha-MeLys(Ac), Lys(Ac), or Glu.

53. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-51, wherein X8 is Gln.

54. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-51, wherein X8 is Lys(Ac).

55. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIa), (VIIb), (VIIc), or (VIId):

Pen- Asn-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (VIIa),


Pen-Gln-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (VIIb),

Abu- Asn-Thr-X7-Gln-Cys-X10-X11-X12-X13-X14-[Pal]-X16 (VIIc) (SEQ ID NO: 448), or

Abu-Gln-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-[Pal]-X16 (VIId),

wherein X7 and X10-X14 are as described in claim 1; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid;

wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

56. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIIa), (VIIIb), (VIIIc), (VIId), (VIIIe), (VIIIf), (VIIIg), or (VIIIh):

Pen- Asn-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-X15-Sarc (VIIIa),

Pen-Gln-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-X15-Sarc (VIIIb),
 Abu- Asn-Thr-X7-Gln-Cys-X10-X11-X12-X13-X14-X15-Sarc (VIIIc),
 Abu-Gln-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-X15-Sarc (VIId),
 Pen- Asn-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIIIe) (SEQ ID NO:
 450),
 Pen-Gln-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIIf) (SEQ ID NO: 451),
 Abu- Asn-Thr-X7-Gln-Cys-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIIIg) (SEQ ID NO:
 452), or
 Abu-Gln-Thr-X7-Gln-Pen-X10-X11-X12-X13-X14-X15-(D)NMeTyr (VIIIh) (SEQ ID NO:
 453),

wherein X7 and X10-X14 are as described in claim 1; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

57. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-56, wherein X10 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-CONH₂).


58. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-56, wherein X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].

59. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-56, wherein X10 is Phe[4-(2-aminoethoxy)].

60. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IXa), (IXb), (IXc), or (IXd):

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-[Pal]-X16 (IXa) (SEQ ID NO:454),
 Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-[Pal]-X16 (IXb) (SEQ ID NO:455),
 Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-X12-X13-X14-[Pal]-X16 (IXc) (SEQ ID NO:456),
 or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-[Pal]-X16 (IXd) (SEQ ID NO:457),
 wherein X7, and X11-X14 are as described in claim 1; F(4-2ae) is Phe[4-(2-aminoethoxy)]; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid;
 wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

61. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Xa), (Xb), (Xc), (Xd), (Xe), (Xf), (Xg), or (Xh):

Pen Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15-Sarc (Xa) (SEQ ID NO: 458),
 Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15-Sarc (Xb) (SEQ ID NO: 459),
 Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-X12-X13-X14-X15-Sarc (Xc) (SEQ ID NO: 460),
 Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15-Sarc (Xd) (SEQ ID NO: 461),
 Pen-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15-(D)NMeTyr (Xe) (SEQ ID NO: 462),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15-(D)NMeTyr (Xf) (SEQ ID NO: 463),

Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-X12-X13-X14-X15-(D)NMeTyr (Xg) (SEQ ID NO: 464), or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15-(D)NMeTyr (Xh) (SEQ ID NO: 465),

wherein X7, and X11-X14 are as described in claim 1; F(4-2ae) is Phe[4-(2-aminoethoxy)]; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

62. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-61, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, Ala, cyclohexylAla, Lys, or Aib.

63. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-61, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, or alpha-MeLeu.

64. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-61, wherein X12 is alpha-MeLeu.

65. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-61, wherein X12 is THP.

66. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-65, wherein X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac); wherein Y2 is an amino acid.

67. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-65, wherein X13 is Glu, Gln, Lys(Ac), or Lys.

68. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-65, wherein X13 is Lys(Ac), or Lys.

69. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-65, wherein X13 is Lys(Ac).

70. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-65, wherein X13 is Glu.

71. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XIa), (XIb), (XIc), or (XId):


Pen-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α-MeLeu]-Lys(Ac)-X14-[Pal]-X16 (XIa) (SEQ ID NO:466),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α-MeLeu]-Lys(Ac)-X14-[Pal]-X16 (XIb) (SEQ ID NO:467),

Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-[α-MeLeu]-Lys(Ac)-X14-[Pal]-X16 (XIc) (SEQ ID NO:468), or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α-MeLeu]-Lys(Ac)-X14-[Pal]-X16 (XId) (SEQ ID NO:469),

wherein X7, X11, and X14, and X14 are as described in claim 1; F(4-2-ae) is Phe[4-(2-aminoethoxy)]; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid; wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

72. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XIIa), (XIIb), (XIIc), or (XIId), (XIIe), (XIIf), (XIIfg), or (XIIfh):

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIa)
(SEQ ID NO:470),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIb)
(SEQ ID NO:471),

Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIc)
(SEQ ID NO:472),

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIId)
(SEQ ID NO:473),

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIe)
(SEQ ID NO:474),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIf)
(SEQ ID NO:475),

Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIfg)
(SEQ ID NO:476), or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-X14-X15-(D)NMeTyr (XIIfh)
(SEQ ID NO:477),

wherein X7, X11, and X14 are as described in claim 1; F(4-2ae) is Phe[4-(2-aminoethoxy)]; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

73. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-72, wherein X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac).

74. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-72, wherein X14 is Asn.

75. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XIIIa), (XIIIb), (XIIIc), or (XIIId):

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XIIIa) (SEQ ID NO:478),


Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XIIIb) (SEQ ID NO:479),

Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XIIIc) (SEQ ID NO:480),

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XIIId) (SEQ ID NO:481),

wherein X7 and X11 are as described in claim 1; F(4-2ae) is Phe[4-(2-aminoethoxy)]; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid;

wherein 2Pal is 2-pyridyl substituted alanine, and 3Pal is 3-pyridyl substituted alanine, and 4Pal is 4-pyridyl substituted alanine



and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

76. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XIVa), (XIVb), (XIVc), (XIVd), (XIVe), (XIVf), (XIVg), or (XIVh):

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XIVa) (SEQ ID NO:482),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XIVb) (SEQ ID NO:483),

Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XIVc) (SEQ ID NO:484), or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XIVd) (SEQ ID NO:485),

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr (XIVe) (SEQ ID NO:486),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr (XIVf) (SEQ ID NO:487),

Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr (XIVg) (SEQ ID NO:488), or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr (XIVh) (SEQ ID NO:489),

wherein X7 and X11 are as described in claim 1; F(4-2-ae) is Phe[4-(2-aminoethoxy)]; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

77. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp unsubstituted or substituted with cyano, halo, alkyl, haloalkyl, hydroxy, alkoxy, phenyl, substituted phenyl, or thienyl; and X11 is as described in claim 1.

78. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, alkoxy, phenyl, substituted phenyl, or thienyl; and the substitution is at 4-, 5-, 6- or 7- position.

79. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with cyano, F, Cl, Br, I, Me, Et, i-Pr, n-Pr, n-Bu, t-Bu, CF₃, hydroxy, OMe, OEt; and the substitution is at 4-, 5-, 6- or 7- position.

80. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-76, wherein X7 is Trp substituted with i) phenyl, unsubstituted or substituted with cyano, halo, alkyl, haloalkyl, aryl hydroxy, alkoxy, or haloalkoxy; or ii) thienyl.

81. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-76, wherein X7 is Trp substituted with phenyl, unsubstituted or substituted with Me, Et, n-Pr, i-Pr, t-Bu, OMe, OEt, Cl, F, CF₃, OCF₃, phenyl, substituted phenyl, or amido.

82. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-76, wherein X7 is Trp substituted with unsubstituted phenyl; or unsubstituted thienyl.

83. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-76, wherein X7 is Trp substituted with 7-Ph

84. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with 5-F, 6-F, 7-F, 5-Cl, 6-Cl, 7-Cl, 5-Me, 6-Me, 7-Me, 5-OH, 6-OH, 7-OH, 5-OMe, 6-OMe, or 7-OMe.

85. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with 7-Me, 5-F, 7-F, 6-Cl, 6-Me, 4-OMe, 5-OMe, or 5-Br.

86. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with 7-Me, 6-Me, 4-OMe, or 6-Cl.

87. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with 7-Me or 7-Ph.

88. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with 7-Me.

89. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-76, wherein X7 is Trp substituted with 7-Ph.

90. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XVa), (XVb), (XVc), or (XVd):

Pen- Asn-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XVa)
(SEQ ID NO:490),

Pen-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XVb)
(SEQ ID NO:491),

Abu- Asn-Thr-[W(7-Me)]-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XVc)
(SEQ ID NO:492), or

Abu-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16 (XVd)
(SEQ ID NO:493),

wherein X11 is as described in claim 1; F(4-2-ae) is Phe[4-(2-aminoethoxy)]; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

91. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XVIa), (XVIb), (XVIc), (XVIId), (XVIE), (XVIIf), (XVIg), or (XVIh):

Pen- Asn-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XVIa)
(SEQ ID NO:494),

Pen-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XVIb)
(SEQ ID NO:495),

Abu- Asn-Thr-[W(7-Me)]-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XVIc)
(SEQ ID NO:496), or

Abu-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc (XVIId)
(SEQ ID NO:497),

Pen- Asn-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr
(XVIE) (SEQ ID NO:498),

Pen-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr
(XVIIf) (SEQ ID NO:499),

Abu- Asn-Thr-[W(7-Me)]-Gln-Cys-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr
(XVIg) (SEQ ID NO:500), or

Abu-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-X11-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr
(XVIh) (SEQ ID NO:501),

wherein X11 is as described in claim 1; F(4-2-ae) is Phe[4-(2-aminoethoxy)]; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

92. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-91, wherein X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.

93. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-91, wherein X11 is 2-Nal, or 1-Nal.

94. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-91, wherein X11 is 2-Nal.

95. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XVIIa), (XVIIb), (XVIIc), or (XVIIId):

Pen- Asn-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16
(XVIIa) (SEQ ID NO:502),

Pen-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16
(XVIIb) (SEQ ID NO:503),

Abu- Asn-Thr-[W(7-Me)]-Gln-Cys-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16
(XVIIc) (SEQ ID NO:504), or

Abu-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-[Pal]-X16
(XVIIId) (SEQ ID NO:505),

wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)]; Pal is 2Pal, 3Pal, or 4Pal; and X16 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

96. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (XVIIIa), (XVIIIb), (XVIIIc), (XVIId), (XVIIIe), (XVIIIf), (XVIIIg), or (XVIIIh):

Pen- Asn-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc
(XVIIIa) (SEQ ID NO:506),

Pen-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc
(XVIIIb), (SEQ ID NO:507)

Abu- Asn-Thr-[W(7-Me)]-Gln-Cys-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc
(XVIIIc) (SEQ ID NO:508),

Abu-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-Sarc
(XVIId) (SEQ ID NO:509),

Pen- Asn-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-
(D)NMeTyr (XVIIIe) (SEQ ID NO:510),

Pen-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-
(D)NMeTyr (XVIIIf) (SEQ ID NO:511),

Abu- Asn-Thr-[W(7-Me)]-Gln-Cys-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-
(D)NMeTyr (XVIIIg) (SEQ ID NO:512), or

Abu-Gln-Thr-[W(7-Me)]-Gln-Pen-[F(4-2ae)]-[2-Nal]-[α -MeLeu]-Lys(Ac)-Asn-X15-(D)NMeTyr (XVIIIh) (SEQ ID NO:513),

wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)]; X15 is any amino acid; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

97. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-96, wherein X15 is 2Pal, 3Pal, 4Pal, His, (D)His, Lys, (D)Lys, Leu, (D)Leu, 2Quin, or 3Quin.

98. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-96, wherein X15 is 3Pal, 4Pal, His, (D)His, (D)Lys or (D)Leu.

99. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-96, wherein X15 is 3Pal, His, (D)Lys or (D)Leu.


100. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-96, wherein X15 is His.

101. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-96, wherein X15 is 3Pal.

102. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-101, wherein X16 is absent.

103. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 90-102, wherein W(7-Me) is replaced with W(7-Ph).


104. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-103, wherein the peptide inhibitor comprises the structure of Formula (Z):



wherein

R^1 is a hydrogen, Ac, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-6alkyl, a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing; X is the amino acid sequence of Formula (I), (Ia), (Ib), (Ic), (Id), or any of Formula (II)-(XVIIIId); and R^2 is OH, NH_2 or N(H)Me.

105. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 104, wherein the peptide inhibitor comprises the structure of Formula (Z'):



wherein

R¹ is a hydrogen, Ac, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-6alkyl, a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing; and R² is OH, NH₂ or N(H)Me.

106. The peptide inhibitor or pharmaceutically acceptable salt thereof claim 105, wherein X4 is (D)Pen, Pen, or Pen(sulfoxide).


107. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 106, wherein X4 is Pen.

108. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 107, wherein X9 is Pen or (D)Pen.

109. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 108, wherein X9 is Pen.

110. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 109, wherein X4 is Pen and X9 is Pen, and the bond is a disulfide bond.

111. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 110, wherein the peptide inhibitor comprises the structure of Formula (Z'):




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

112. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 111, wherein X5 is Asn, Ser, Gln, or Glu.

113. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 112, wherein X5 is Asn.


114. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 113, wherein the peptide inhibitor comprises the structure of Formula (Z'):



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

115. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 114, wherein X6 is Thr.

116. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 115, wherein the peptide inhibitor comprises the structure of Formula (Z'):




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

117. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 116, wherein X8 is Gln, alpha-Me-Lys, alpha-MeLys(Ac), Lys(Ac), or Glu.

118. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 117, wherein X8 is Lys(Ac).

119. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 118, wherein the peptide inhibitor comprises the structure of Formula (Z'):



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

120. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 119, wherein X10 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-CONH₂).

121. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 120, wherein X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].

122. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 121, wherein X10 is Phe[4-(2-aminoethoxy)].

123. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 122, wherein the peptide inhibitor comprises the structure of Formula (Z'):

$$R^1\text{-X3-Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]\text{-X11-X12-X13-X14-X15-X16-R}^2 \text{ (Z'-E) (SEQ}$$

ID NO:514)


wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

124. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 123, wherein X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.

125. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 124, wherein X11 is 2-Nal, or 1-Nal.

126. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 125, wherein X11 is 2-Nal.

127. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 126, wherein the peptide inhibitor comprises the structure of Formula (Z'):




wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

128. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 127, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, Ala, cyclohexylAla, Lys, or Aib.

129. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 128, wherein X12 is THP.

130. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 129, wherein the peptide inhibitor comprises the structure of Formula (Z'):




wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

131. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 130, wherein X13 is Glu, Gln, Lys(Ac), or Lys.

132. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 131, wherein X13 is Glu.

133. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 132, wherein the peptide inhibitor comprises the structure of Formula (Z'):



wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

134. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 133, wherein X14 is Asn.

135. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 134, wherein the peptide inhibitor comprises the structure of Formula (Z'):

R^1 -X3-Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-[2-Nal]-THP-Glu-Asn-X15-X16- R^2 (Z'-I)
(SEQ ID NO:518)

wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

136. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 135, wherein X7 is Trp or Trp substituted with alkyl, or phenyl; and the substitution is at the 4-, 5-, 6- or 7- position.

137. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 136, wherein X7 is Trp or Trp substituted with Me, Et, i-Pr, n-Pr, n-Bu, t-Bu, or phenyl; and the substitution is at the 4-, 5-, 6- or 7- position.

138. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 137, wherein X7 is Trp or Trp substituted with 5-Me, 6-Me, 7-Me, 5-phenyl, 6-phenyl or 7-Ph.

139. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 138, wherein X7 is Trp or Trp substituted with 7-Me, 6-Me, or 7-Ph.

140. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 139, wherein X7 is Trp or Trp substituted with 7-Me or 7-Ph.

141. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 140, wherein X7 is Trp substituted with 7-Me.

142. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 141, wherein the peptide inhibitor comprises the structure of Formula (Z'):

R^1 -X3-Pen-Asn-Thr-[W(7-Me)]-Lys(Ac)-Pen-[F(4-2ae)]-[2-Nal]-THP-Glu-Asn-X15-X16- R^2
(Z'-J)

wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

143. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 142, wherein X3 is absent or (D)Arg.

144. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 143, wherein X3 is absent.

145. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 143, wherein X3 is (D)Arg.

146. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 143, wherein the peptide inhibitor comprises the structure of Formula (Z'): R^1 -Pen-Asn-Thr-[W(7-Me)]-Lys(Ac)-Pen-[F(4-2ae)]-[2-Nal]-THP-Glu-Asn-X15-X16- R^2 (Z'-K) wherein F(4-2ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

147. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim 105, wherein
X3 is absent or (D)Arg;
X4 is Abu, Cys, (D)Cys, alpha-McCys, or Pen;
X5 is Ala, (allyl)Gly, Ile, Leu, Asn, Nle, or Gln;
X6 is Asp, or Thr;
X7 is (7-methyl)Trp, (4-F)Trp, or Trp;
X8 is Cit, Lys(Ac), Lys(Benzyl, Ac), Lys(butyl, Ac), Lys(isobutyl,Ac), Lys(propyl,Ac),Gln, 4-adamantyl-Phe, (4-AcNH)Phe, or Tyr;
X9 is Cys, alpha-McCys, or Pen;
X10 is Phe or substituted Phe, Tyr or substituted Tyr;
X11 is 2-Nal;
X12 is 4-amino-4-carboxy-tetrahydropyran (THP), Acpx, Acvc, alpha-MeLys, or alpha-MeLeu;
X13 is alpha-methylGlu, Glu, or Lys(Ac); and
X14 is Asn.

148. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 104 to 147, wherein R^1 is H or C1-C20 alkanoyl.

149. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 104 to 148, wherein R^1 is H or Ac.

150. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 104 to 149, wherein R^1 is Ac.

151. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 104 to 150, wherein R^2 is NH_2 or N(H)Me.

152. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 104 to 151, wherein R^2 is NH_2 .

153. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 151, wherein

R¹ is Ac;
X3 is absent or (D)Arg;
X4 is Pen;
X5 is Asn;
X6 is Thr;
X7 is Trp or (7-Me)Trp or (7-Ph)Trp;
X8 is Lys(Ac);
X9 is Pen;
X10 is Phe(2-aminoethoxy);
X11 is 2-Nal;
X12 is 4-amino-4-carboxy-tetrahydropyran (THP);
X13 is Gln;
X14 is Asn; and
R² is NH₂ or N(H)Me.

154. The peptide inhibitor or pharmaceutically acceptable salt thereof of claim

153, wherein

R¹ is Ac;
X3 is absent;
X4 is Pen;
X5 is Asn;
X6 is Thr;
X7 is 7-methylTrp;
X8 is Lys(Ac);
X9 is Pen;
X10 is Phe(2-aminoethoxy);
X11 is 2-Nal;
X12 is 4-amino-4-carboxy-tetrahydropyran (THP);
X13 is Glu;
X14 is Asn; and
R² is NH₂ or N(H)Me.

155. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 154, wherein

X15 is Aib, beta-Ala, (D)Phe, (D)Lys, (D)Leu, (D)Orn, substituted (D)Phe, (D)Arg, (D)Val, (D)Tyr, Phe, Hph, Asn, 4-amino-4-carboxy-tetrahydropyran (THP), substituted Tyr, or Tyr; and X16 is beta-Ala, (D)NMeTyr, (D)Pro, NMeTyr, Pro, or Sarc.

156. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 154, wherein

X15 is 3Pal, substituted 3Pal, 4Pal, 4-triazole-Ala, (D)His, His or substituted His; and X16 is absent, Aib, alpha-MePro, (D)Leu, (D)NMeTyr, (D)Pro, (D)Tyr, substituted Gly, MeLeu, MeNLe, Pro, Paf, 4-di-fluoro-Pro, Sarc, or Tyr.


157. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 154 or 156, wherein

X15 is (D)His, substituted His, 2Pal, 3Pal, 4Pal, 4TriazolAla, or 5Pyal; and X16 is absent, (D)NMeTyr or Sarc.

158. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 154, 156 or 157, wherein

X15 is (3-Me)His or 3Pal; and X16 is absent or Sarc.

159. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 154 or 156 to 158, wherein the peptide inhibitor comprises the structure of Formula (Z'):



wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

160. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 159, wherein the peptide inhibitor comprises the structure of Formula (Z'):

$$\text{Ac-Pen-Asn-Thr-[W(7-Me)]-Lys(Ac)-Pen-[F(4-2ae)]-[2-Nal]-THP-Glu-Asn-X15-Sarc-NH}_2 (\text{Z}'\text{-M})$$

wherein F(4-2-ae) is Phe[4-(2-aminoethoxy)], and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond.

161. The peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 105 to 154 or 156 to 160, wherein X15 is 3Pal; and X16 is Sarc.

162. A peptide inhibitor of an interleukin-23 receptor, wherein the peptide inhibitor comprises or is any one of the amino acid sequence set forth in any of Table E1A and Table E1B; or a pharmaceutically acceptable salt thereof.

163. The peptide inhibitor of claim 162, wherein the peptide inhibitor comprises or is any one of the amino acid sequence listed below:

Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Ph)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-dK-[Sarc]-NH₂ (SEQ ID NO:1);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3-Quin]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:2);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3-Quin]-[THP]-E-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:3);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3-Quin]-[a-MeLys]-[Lys(Ac)]-N-[(D)His]-[Sarc]-NH₂ (SEQ ID NO:4);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3-Quin]-[a-MeLys]-[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:5);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3-Quin]-[THP]-E-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:6);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3-Quin]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:7);

Ac-[(D)Arg]-[Abu]-Q-T-W-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-N-[(D)NMeTyr]-NH₂ (SEQ ID NO:8);

Ac-[(D)Arg]-[Pen]-Q-T-W-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-N-[(D)NMeTyr]-NH₂ (SEQ ID NO:9);

Ac-[(D)Arg]-[Pen]-Q-T-W-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[aMeGlu]-N-F-[(D)NMeTyr]-NH₂ (SEQ ID NO:10);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[THP]-E-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:11);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:12);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[THP]-E-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:13);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:14);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:15);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[a-MeLys]-[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:16);

Ac-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:17);

Ac-[Abu]-Q-T-[W(7-Ph)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:18);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:20);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂ (SEQ ID NO:21);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:22);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:23);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:24);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:25);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:26);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:27);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:28);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:29);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(bAla)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:30);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(bAla)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:31);

Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:32);

Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:33);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(7-Et)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:34);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(4-Me)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:35);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(6-Me)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:36);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(4-OMe)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:37);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(7-i-Pr)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:38);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(7-nPr)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:39);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(7-OMe)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:40);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(6-Cl)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:41);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(5-OMe)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:42);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(3-MePh)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:43);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(6-Ph)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:44);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(6-Et)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:45);
Ac-[Pen]-N-T-[W(7-(2-FPh))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:46);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-[(D)NMeTyr]-NH₂ (SEQ ID NO:47);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Lys]-[(D)NMeTyr]-NH₂ (SEQ ID NO:48);
Ac-[Pen]-N-T-[W(7-(2-OMePh))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:49);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(7-Ph)]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:50);
Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:51);
Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:52);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:53);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-H-
[Sarc]-NH₂ (SEQ ID NO:54);
Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:55);
Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-H-
[Sarc]-NH₂ (SEQ ID NO:56);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[(D)NMeTyr]-NH₂ (SEQ ID NO:57);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-F-[(D)NMeTyr]-NH₂ (SEQ ID NO:58);
Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-H-
[Sarc]-NH₂ (SEQ ID NO:59);
Ac-[Pen]-S-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:60);
Ac-[Pen]-S-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-H-
[Sarc]-NH₂ (SEQ ID NO:61);
Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[(D)NMeTyr]-NH₂ (SEQ ID NO:62);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-[(D)Asn]-
H-[Sarc]-NH₂ (SEQ ID NO:63);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-G-H-
[Sarc]-NH₂ (SEQ ID NO:64);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-[h(Ser)]-
H-[Sarc]-NH₂ (SEQ ID NO:65);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-P-
NH₂ (SEQ ID NO:66);

Ac-[Pen]-N-T-[W(7-(2-Nal))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:67);

Ac-[Pen]-N-T-[W(7-3BiPh)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:68);

Ac-[Pen]-N-T-[W(7-(Phenanthren-5-yl))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:69);

Ac-[Pen]-N-T-[W(7-(4-Anthracen-5-yl))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:70);

Ac-[Pen]-N-T-[W(7-(1-Nal))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:71);

Ac-[Pen]-N-T-[W(7-(4BiPh))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:72);

Ac-[Pen]-N-T-[W(7-(3,5-t-Bu-Ph))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:73);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CONH₂)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:74);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:75);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[3Quin]-[a-MeLys]-[Lys(Ac)]-N-[2Pal]-NH₂ (SEQ ID NO:78);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[2Pal]-NH₂ (SEQ ID NO:79);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-NH₂ (SEQ ID NO:80);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:81);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-[(D)NMeTyr]-NH₂ (SEQ ID NO:82);

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-N-H-[(D)NMeTyr]-NH₂ (SEQ ID NO:83);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-Phe[4-aminomethyl]-[(D)NMeTyr]-NH₂ (SEQ ID NO:84);

Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-[Lys(Ac)]-N-[(D)His]-NH₂ (SEQ ID NO:85);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)His]-NH₂ (SEQ ID NO:86);
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[(D)His]-[(D)NMeTyr]-NH₂ (SEQ ID NO:87);
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-N-[(D)NMeTyr]-NH₂ (SEQ ID NO:88);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-N-[(D)NMeTyr]-NH₂ (SEQ ID NO:89);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Val]-[(D)NMeTyr]-NH₂ (SEQ ID NO:90);
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Thr]-[(D)NMeTyr]-NH₂ (SEQ ID NO:91);
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[(D)His]-NH₂ (SEQ ID NO:92);
Ac-[Abu]-N-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[3Quin]-[THP]-E-N-H-[Sarc]-NH₂
(SEQ ID NO:93);
Ac-[Abu]-N-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[3Quin]-[THP]-E-N-H-[Sarc]-NH₂
(SEQ ID NO:94);
Ac-[Abu]-N-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-
[Sarc]-NH₂ (SEQ ID NO:95);
Ac-[Abu]-N-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[Sarc]-NH₂
(SEQ ID NO:96);
Ac-[Abu]-N-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-H-[Sarc]-NH₂ (SEQ ID NO:97);
Ac-[Abu]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:98);
Ac-[Abu]-N-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:99);
Ac-[(D)Arg]-[Abu]-S-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:100);
Ac-[(D)Arg]-[Abu]-N-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-
[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:101);
Ac-[(D)Arg]-[Abu]-N-T-[W(7-Me)]-[Cit]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-
[Sarc]-NH₂ (SEQ ID NO:102);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:103);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:104);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:105);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:106);

Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:107);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-
NH₂ (SEQ ID NO:108);

Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-
NH₂ (SEQ ID NO:109);

Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-
[3Pal]-[Sarc]-NH₂ (SEQ ID NO:110);

Ac-[Abu]-Q-T-[W(7-Me)]-[Cit]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:111);

Ac-[Abu]-Q-T-[W(7-Me)]-[Cit]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:112);

Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[bA]-
NH₂ (SEQ ID NO:113);

Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-[3Pal]-[bA]-
NH₂ (SEQ ID NO:114);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[4Pal]-
[Sarc]-NH₂ (SEQ ID NO:115);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[bA]-NH₂ (SEQ ID NO:116);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-
[3Pal]-[Sarc]-NH₂ (SEQ ID NO:117);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-
[3Quin]-[Sarc]-NH₂ (SEQ ID NO:118);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[7-
Aza-tryptophan]-[Sarc]-NH₂ (SEQ ID NO:119);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[3Pal]-[(D)NMeTyr]-NH₂ (SEQ ID NO:120);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[(D)NMeTyr]-NH₂ (SEQ ID NO:121);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[3Pal]-[(D)NMeTyr]-NH₂ (SEQ ID NO:122);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[(D)NMeTyr]-NH₂ (SEQ ID NO:123);

Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:124);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:125);

Ac-[Pen]-N-T-[W(7-Ph)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-
NH₂ (SEQ ID NO:126);

Ac-[Pen]-N-T-[W(7-Ph)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-
NH₂ (SEQ ID NO:127);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[3Pal]-[bA]-NH₂ (SEQ ID NO:130);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[bA]-NH₂ (SEQ ID NO:131);

Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-
[Sarc]-NH₂ (SEQ ID NO:132);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-
N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:133);

Ac-[Abu]-Q-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-
NH₂ (SEQ ID NO:134);

Ac-[Abu]-Q-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-
[3Pal]-[Sarc]-NH₂ (SEQ ID NO:135);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-
[3Pal]-[Sarc]-NH₂ (SEQ ID NO:136);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aceylaminoethoxy)]-[2-Nal]-[THP]-
[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:137);

Ac-[Pen]-E-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-
N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:138);

Ac-[Pen]-E-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:139);

Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:140);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:141);

Ac-[Pen]-N-T-[W(7-(3-carboxamidophenyl))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:142);

Ac-[Pen]-N-T-[W(7-pyrimidin-5-yl)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:143);

Ac-[Pen]-N-T-[W(7-imidazopyridinyl)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:144);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[NMe(Lys)]-[Lys(Ac)]-N-[His_3Me]-NH₂ (SEQ ID NO:145);

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[His_3Me]-NH₂ (SEQ ID NO:146);

Ac-[Pen]-N-T-[W(7-(4Quin))]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:147);

Ac-[Pen]-N-T-[(W(7-(3-pyrazol-1-yl)))-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:148);

Ac-[Pen]-N-T-[(W(7-(5-Et)))-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:149);

Ac-[Pen]-N-T-[W(5-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:150);

Ac-[Pen]-N-T-[(W(7-(3-pyrazol-1-yl)))-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:151);

Ac-[Pen]-N-T-[W(7-indazol-5-yl)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:152);

Ac-[Pen]-N-T-[W(4-F)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:153);

Ac-[Pen]-N-T-[W(5-CN)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:154);

Ac-[Pen]-N-T-[W(7-CN)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:155);

Ac-[Pen]-N-T-[W(4-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:156);

Ac-[Pen]-N-T-[W(4-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:157);

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:158);

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:159, 285);

Ac-[Pen]-N-T-[W(5-Ca)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:160);

Ac-[Pen]-N-T-[Trp_4Aza]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:161);

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:162);

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:163);

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[(5Pyl)]-NH₂ (SEQ ID NO:164);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-Me-Lys]-[Lys(Ac)]-N-[(5Pyl)]-NH₂ (SEQ ID NO:165);

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[(1-Me)His]-NH₂ (SEQ ID NO:166);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLys]-[Lys(Ac)]-N-[(1-Me)His]-NH₂ (SEQ ID NO:167); or

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-Me-Lys]-[Lys(Ac)]-N-[3Pal]-[(D)NMeTyr]-NH₂ (SEQ ID NO:168);

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;

or a pharmaceutically acceptable salt thereof.

164. The peptide inhibitor of claim 163, wherein the peptide comprises or is:

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-NH₂ (SEQ ID NO:80);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:104);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:108);

Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:110);

Ac-[Abu]-Q-T-[W(7-Me)]-[Cit]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:112);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Quin]-[Sarc]-NH₂ (SEQ ID NO:118);

Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:124); or

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-S-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:125);

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;

or a pharmaceutically acceptable salt thereof.

165. The peptide inhibitor of claim 163, wherein the peptide comprises or is:

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:105);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:106);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:117);

Ac-[Pen]-N-T-[W(7-Ph)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:126);

Ac-[Pen]-N-T-[W(7-Ph)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:127);

Ac-[Abu]-Q-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:134);

Ac-[Abu]-Q-T-[W(7-Ph)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:135);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:136);

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aceylaminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:137); or

Ac-[Pen]-E-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:139);

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;

or a pharmaceutically acceptable salt thereof.

166. The peptide inhibitor of claim 162, wherein the peptide inhibitor comprises or is any one of the amino acid sequence listed below:

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-E-N-[(D)Lys]-[(D)NMeTyr]-NH₂ (SEQ ID NO:201),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-E-N-[(D)His]-[(D)NMeTyr]-NH₂ (SEQ ID NO:202),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Orn]-[(D)NMeTyr]-NH₂ (SEQ ID NO:203),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-[(D)NMeTyr]-NH₂ (SEQ ID NO:204),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-[(D)NMeTyr]-NH₂ (SEQ ID NO:205),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[(D)Tyr]-NH₂ (SEQ ID NO:206),

Ac-[Pen]-N-T-[W(7-Me)]-[(D)Tyr]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[(D)NMeTyr]-NH₂ (SEQ ID NO:207),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-P-NH₂ (SEQ ID NO:208),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-[(D)Pro]-NH₂ (SEQ ID NO:209),

Ac-[Pen]-N-T-[W(7-Me)]-[Phe(4-CONH₂)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[(D)NMeTyr]-NH₂ (SEQ ID NO:210),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-(D)Phe[4-NH₂]-[Sarc]-NH₂ (SEQ ID NO:211),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-H-NH₂ (SEQ ID NO:212),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-N(H)Me (SEQ ID NO:213),
Ac-[Pen]-N-T-[W(7-Me)]-[Phe(4-NH(Ac))]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[(D)NMeTyr]-NH₂ (SEQ ID NO:214),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-[(D)NMeTyr]-NH₂ (SEQ ID NO:215),
Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[aMeLeu]-[Lys(Ac)]-N-[(D)Lys]-[(D)NMeTyr]-NH₂ (SEQ ID NO:216),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)His]-[(D)NMeTyr]-NH₂ (SEQ ID NO:217),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bAla]-[(D)NMeTyr]-NH₂ (SEQ ID NO:218),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bAla]-[(D)NMeTyr]-NH₂ (SEQ ID NO:219),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bAla]-[(D)NMeTyr]-NH₂ (SEQ ID NO:220),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-N-H-N(H)Me (SEQ ID NO:221),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[THP]-P-NH₂ (SEQ ID NO:222),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[THP]-[(D)Pro]-NH₂ (SEQ ID NO:223),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[bAla]-[Sarc]-NH₂ (SEQ ID NO:224),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[(D)Val]-[Sarc]-NH₂ (SEQ ID NO:225),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[(D)Arg]-[Sarc]-NH₂ (SEQ ID NO:226),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[Hph]-[Sarc]-NH₂ (SEQ ID NO:227),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-Phe[4-NH₂]-[Sarc]-NH₂ (SEQ ID NO:228),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-Phe[4-NH₂]-[Sarc]-NH₂ (SEQ ID NO:229),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-F-[Sarc]-NH₂ (SEQ ID NO:230),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[THP]-[Sarc]-NH₂ (SEQ ID NO:231),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:232),

Ac-[(D)Arg]-[Cys]-N-T-[W(7-Me)]-[Lys(Ac)]-[aMeCys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-H-[Sarc]-NH₂ (SEQ ID NO:233),

Ac-[(D)Arg]-[Cys]-N-T-[W(7-Me)]-[Lys(Ac)]-[aMeCys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[(D)Leu]-[Sarc]-NH₂ (SEQ ID NO:234),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:235),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bAla]-[Sarc]-NH₂ (SEQ ID NO:236),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Val]-[Sarc]-NH₂ (SEQ ID NO:237),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Arg]-[Sarc]-NH₂ (SEQ ID NO:238),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Hph]-[Sarc]-NH₂ (SEQ ID NO:239),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-[Sarc]-NH₂ (SEQ ID NO:240),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-[Sarc]-NH₂ (SEQ ID NO:241),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[4Pal]-NH₂ (SEQ ID NO:242),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Phe(4-CF₃)]-[Sarc]-NH₂ (SEQ ID NO:243),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-Tyr_CHF₂-[Sarc]-NH₂ (SEQ ID NO:244),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[THP]-P-NH₂ (SEQ ID NO:245),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[3Pal]-[(D)NMeTyr]-NH₂ (SEQ ID NO:246),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:247),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[4Pal]-[Sarc]-NH₂ (SEQ ID NO:248),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[Phe(2-aminomethyl)]-[Sarc]-NH₂ (SEQ ID NO:249),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal]-[Pro(4,4diF)]-NH₂ (SEQ ID NO:250),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal]-[aMePro]-NH₂ (SEQ ID NO:251),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal]-[Aib]-NH₂ (SEQ ID NO:252),
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[His(3-Me)]-[Sarc]-NH₂ (SEQ ID NO:253),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[His(3-Me)]-[Sarc]-NH₂ (SEQ ID NO:261),
Ac-[(D)Arg]-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-
[His(3-Me)]-[Sarc]-NH₂ (SEQ ID NO:262),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:266),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal]-N(H)Me (SEQ ID NO:267),
[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-
[3Pal]-[Sarc]-NH₂ (SEQ ID NO:270),
Ac-[(D)Arg]-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-
[3Pal]-[Sarc]-NH₂ (SEQ ID NO:271),
Pr-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-(N-propionylamino)ethoxy)]-[2-
Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:272),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-(N-(4-hydroxy-3-methylphenyl)
propionylamino)ethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:273),
Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-
N-[3Pal(5-Me)]-[Sarc]-NH₂ (SEQ ID NO:276),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal(5-NH₂)]-[Sarc]-NH₂ (SEQ ID NO:277),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[His(3-Me)]-N(H)Me (SEQ ID NO:278),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[(D)NMeTyr]-NH₂ (SEQ ID NO:279),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Gly(N-cyclohexylmethyl)]-NH₂ (SEQ ID NO:280),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Gly(N-isobutyl)]-NH₂ (SEQ ID NO:281),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal(3-Me)]-NH₂ (SEQ ID NO:282),

Ac-[(D)Arg]-[aMeCys]-N-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:283),

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:284),

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acvc]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:285, 159),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CONH₂)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:286),

Ac-[Pen]-[Gly(Allyl)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Tyr(O-Allyl)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:287),

Ac-[Pen]-[Gly(Allyl)]-D-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Tyr(O-Allyl)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:288),

Ac-[Pen]-[Gly(Allyl)]-T-(W(4-F))-[Lys(Ac)]-[Pen]-[Tyr(O-Allyl)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:289),

Ac-[Pen]-N-D-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:290),

Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:291),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CONH₂)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:299),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:308),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[(D)Tyr]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:309),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:310),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CONH₂)]-[2-Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:311),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(N-acetyl-N-propyl)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:332),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(N-acetyl-N-butyl)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:333),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(N-acetyl-N-isobutyl)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:334),

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(N-acetyl-N-benzyl)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:335),

Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CONH₂)]-[2-Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:339),

Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[2-Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:347), or

Ac-[Abu]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:373),

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;

or a pharmaceutically acceptable salt thereof.

167. The peptide inhibitor of claim 163 or 166, wherein the peptide is

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:104),

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:106),

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NOs:158, 162, 284),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NOs:247, 266),

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[His(3-Me)]-[Sarc]-NH₂ (SEQ ID NO:261), or

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-N(H)Me (SEQ ID NO:267),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,

or a pharmaceutically acceptable salt thereof.

168. The peptide inhibitor of claim 167, wherein the peptide is

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:104),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,

or a pharmaceutically acceptable salt thereof.

169. The peptide inhibitor of claim 167, wherein the peptide is

Ac-[Pen]-N-T-[W(7-Ph)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NO:106),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,

or a pharmaceutically acceptable salt thereof.

170. The peptide inhibitor of claim 167, wherein the peptide is

Ac-[Pen]-N-T-W-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ (SEQ ID NOs:158, 162, 284),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,

or a pharmaceutically acceptable salt thereof.

171. The peptide inhibitor of claim 167, wherein the peptide is

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH₂ SEQ ID NOs:247, 266),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,

or a pharmaceutically acceptable salt thereof.

172. The peptide inhibitor of claim 167, wherein the peptide is

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[His(3-Me)]-[Sarc]-NH₂ (SEQ ID NO:261),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,

or a pharmaceutically acceptable salt thereof.

173. The peptide inhibitor of claim 167, wherein the peptide is

Ac-[(D)Arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3Pal]-N(H)Me (SEQ ID NO:267),

wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond,
or a pharmaceutically acceptable salt thereof.

174. A polynucleotide comprising a sequence encoding the peptide inhibitor of any one of claims 1-173.

175. A vector comprising the polynucleotide of claim 174.

176. A pharmaceutical composition comprising the peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-173, and a pharmaceutically acceptable carrier, excipient, or diluent.

177. The pharmaceutical composition of claim 176, further comprising an enteric coating.

178. The pharmaceutical composition of claim 177, wherein the enteric coating protects and releases the pharmaceutical composition within a subject's lower gastrointestinal system.

179. A method for treating an Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (*nontropical Sprue*), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, or graft versus host disease in a subject, comprising providing to the subject an effective amount of the peptide inhibitor or peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-173, or the pharmaceutical composition of any one of claims 176-178.

180. The method of claim 179, wherein the pharmaceutical composition is provided to the subject by an oral, parenteral, intravenous, peritoneal, intradermal, subcutaneous, intramuscular, intrathecal, inhalation, vaporization, nebulization, sublingual, buccal, parenteral, rectal, intraocular, inhalation, topically, vaginal, or topical route of administration.

181. The method of claim 179 for treating Inflammatory Bowel Disease (IBD), ulcerative colitis, or Crohn's disease, wherein the pharmaceutical composition is provided to the subject orally.

182. The method of claim 179 for treating psoriasis, wherein the pharmaceutical composition is provided to the subject orally, topically, parenterally, intravenously, subcutaneously, peritoneally, or intravenously.

183. The peptide inhibitor or peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-173, or the pharmaceutical composition of any one of claims 176-178, for use in the treatment of an Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (*nontropical Sprue*), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, or graft versus host disease in a subject, comprising providing to the subject an effective amount of the peptide inhibitor or peptide inhibitor or pharmaceutically acceptable salt thereof of any one of claims 1-173, or the pharmaceutical composition of any one of claims 176-178.

184. The composition for use according to claim 183, wherein the pharmaceutical composition is provided to the subject by an oral, parenteral, intravenous, peritoneal, intradermal, subcutaneous, intramuscular, intrathecal, inhalation, vaporization, nebulization, sublingual, buccal, parenteral, rectal, intraocular, inhalation, topically, vaginal, or topical route of administration.

185. The composition for use according to claim 183 for treating Inflammatory Bowel Disease (IBD), ulcerative colitis, or Crohn's disease, wherein the pharmaceutical composition is provided to the subject orally.

186. The composition for use according to claim 183 for treating psoriasis, wherein the pharmaceutical composition is provided to the subject orally, topically, parenterally, intravenously, subcutaneously, peritoneally, or intravenously.